Abstract
The damage of axons and neurons in multiple sclerosis (MS) is well recognised and correlates with neurological disability. The reasons leading to axonal and neuronal injury are diverse and possibly change from an inflammatory mediated mechanism to a neurodegenerative mechanism over the course of the disease. Acute axonal injury is associated with inflammation in the CNS and thus immunomodulatory treatments may also protect neurons from further damage. However, more effective immune treatments also bear the risk for severe side effects. Thus, neuroprotection will become more important to be combined with safe immunomodulation. Although several targets for neuroprotection have been identified experimentally, the translation into clinical treatments proves very difficult. Only few and small trials have investigated substances that may be neuroprotective, however, none had proven to have a substantial effect in MS patients. Clinical trials of remyelination, considered as a natural way of neuroprotection, were likewise not able to achieve clinical benefit. Thus, the development of a neuroprtective treatment in MS will be a major challenge in the decades to come.
Keywords: Neurodegeneration, axonal injury, neuroprotection, clinical trial, remyelination, repair, axons, neurons, multiple sclerosis (MS), CNS.
Current Pharmaceutical Design
Title:Neurodegeneration and Neuroprotection in Multiple Sclerosis
Volume: 18 Issue: 29
Author(s): Martin Stangel
Affiliation:
Keywords: Neurodegeneration, axonal injury, neuroprotection, clinical trial, remyelination, repair, axons, neurons, multiple sclerosis (MS), CNS.
Abstract: The damage of axons and neurons in multiple sclerosis (MS) is well recognised and correlates with neurological disability. The reasons leading to axonal and neuronal injury are diverse and possibly change from an inflammatory mediated mechanism to a neurodegenerative mechanism over the course of the disease. Acute axonal injury is associated with inflammation in the CNS and thus immunomodulatory treatments may also protect neurons from further damage. However, more effective immune treatments also bear the risk for severe side effects. Thus, neuroprotection will become more important to be combined with safe immunomodulation. Although several targets for neuroprotection have been identified experimentally, the translation into clinical treatments proves very difficult. Only few and small trials have investigated substances that may be neuroprotective, however, none had proven to have a substantial effect in MS patients. Clinical trials of remyelination, considered as a natural way of neuroprotection, were likewise not able to achieve clinical benefit. Thus, the development of a neuroprtective treatment in MS will be a major challenge in the decades to come.
Export Options
About this article
Cite this article as:
Stangel Martin, Neurodegeneration and Neuroprotection in Multiple Sclerosis, Current Pharmaceutical Design 2012; 18 (29) . https://dx.doi.org/10.2174/138161212802502189
DOI https://dx.doi.org/10.2174/138161212802502189 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Physiological and Pathological Functions of Acid-Sensing Ion Channels in the Central Nervous System
Current Drug Targets Does the Vitamin D Deficiency Have Any Role in Severity or Prolongation of Seizure? A Pilot Study in Iran
Current Nutrition & Food Science Adaptive Behavior in Williams-Beuren Syndrome, Down Syndrome, and Autism Spectrum Disorder
Current Psychiatry Reviews Trends in Mitochondrial Therapeutics for Neurological Disease
Current Medicinal Chemistry Carvacrol as a Potential Neuroprotective Agent for Neurological Diseases: A Systematic Review Article
CNS & Neurological Disorders - Drug Targets VEGF Signaling Regulates Cofilin and the Arp2/3-complex within the Axonal Growth Cone
Current Neurovascular Research Allosteric Modulators for Adenosine Receptors: An Alternative to the Orthosteric Ligands
Current Topics in Medicinal Chemistry Neuroprotective Properties of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) and its Lipid Ligands
Current Medicinal Chemistry Thymoquinone: A Review on its Pharmacological Importance, and its Association with Oxidative Stress, COVID-19, and Radiotherapy
Mini-Reviews in Medicinal Chemistry Thalamocortical Oscillations: Local Control of EEG Slow Waves
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Neuroinflammation a Common Link in Neurodegenerative Neurological and Psychiatric Disorders)
Current Pharmaceutical Design PET Imaging in Clinical Drug Abuse Research
Current Pharmaceutical Design MicroRNA Therapeutics in Neurological Disease
Current Pharmaceutical Design Evaluation of Selected Nigerian Medicinal Plants for in vitro Antiprotozoal Activity
The Natural Products Journal A Salicylic Acid-Based Analogue Discovered from Virtual Screening as a Potent Inhibitor of Human 20α-Hydroxysteroid Dehydrogenase
Medicinal Chemistry The Glial Sodium-Calcium Exchanger: A New Target for Nitric Oxide- Mediated Cellular Toxicity
Current Protein & Peptide Science Local Cerebral Blood Flow is Preserved in Sepsis
Current Neurovascular Research Effects on the Post-translational Modification of H3K4Me3, H3K9ac, H3K9Me2, H3K27Me3, and H3K36Me2 Levels in Cerebral Cortex, Hypothalamus and Pons of Rats after a Systemic Administration of Cannabidiol: A Preliminary Study
Central Nervous System Agents in Medicinal Chemistry Moxifloxacin Hydrochloride-Loaded Eudragit® RL 100 and Kollidon® SR Based Nanoparticles: Formulation, In vitro Characterization and Cytotoxicity
Combinatorial Chemistry & High Throughput Screening Synthesis and Evaluation of In Vivo Anticonvulsant Activity of 2,5- Disubstituted-1,3,4-Oxadiazole Derivatives
Letters in Drug Design & Discovery